Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026

Published by KuicK Research Product code 989758
Published Content info 500 Pages
Delivery time: 1-2 business days
Price
Back to Top
US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026
Published: February 17, 2021 Content info: 500 Pages
Description

"US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026" Report Highlights:

  • US Diabetes Drugs Market & Clinical Trial Insight
  • Comprehensive Insight On Approved Diabetes Drugs Price & Dosage Analysis For US Market
  • Diabetes Drugs Patent Timeline
  • Dosage, Formulation, Patent, Pricing Insight by Drug Class
  • 500 Page Data & Analysis On All Approved Drugs In Market

The US pharmaceutical market will continue to see a focus on the transformation of the diabetes market at an unprecedented rate. The overall transformation led down by the country is about using the therapeutics platform symbiotically as well as strategically to extract and unravel hidden information associated with the disease. Diabetes market in the country is fast becoming the largest contributor to the US pharmaceutical market and hundreds of biotech and bio-pharma companies are building novel strategies for the future. The US diabetes market is believed to be the outcome of the advancement in the therapeutics sector as arrival of hundreds of potent drugs have significantly improved the total patient outcomes. Over the past few years, much work and extensive investment have been done in the diabetes research and development across industry and academia, resulting in a complete focused area for major key players.

vThe US over the past few years has also observed large number of diabetes cases, thus making the market deliver opportunities with respect to diabetes disease targets with high premium deals. With more than hundreds of clinical compounds in development (which consists of approximately half of the global clinical compounds), the US is also considered as a global leader in the clinical platform associated with the market. In addition, the abundant organic research and development at different clinical-stage biotechs and large bio-pharmaceutical companies is also observed to unbox spate of multibillion dollar diabetes focused acquisitions and partnerships, thus making the US observe a market growth rate that is splendid.

The high clinical promising prospects is believed to be sufficiently transformative in inclining the country towards receiving success over the next several decades. Specific trends followed in the country for the market such as high value deals are observed to get repeated in the future years, thus assessing the future shape of the market in delivering healthcare benefits to global patients. The current success rate in diabetes, with an average launch timeline of several drugs is observed to make up over a large percentage of global percentage of diabetes drugs launched every year.

As per the "US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026" report findings related to US diabetes drug market, it is concluded that the US diabetes market will make the future of the global diabetes market more intense. With more than several clinical compounds in development, the US diabetes market is believed to provide some novel assets to the global market, thus captivating a phase for market that is tremendous and capable of growing at a double-digit compound annual growth rate. The overall strategic alliances adopted by major and local drug makers in the country are also leading to the biosynthesis of the drugs capable of holding trending opportunities for the patients. Despite of having a rigid competition from other pharmaceutical market such as Europe, the stages of development of the market followed by the country researchers are bound to fetch more latest innovation and attention from other leaders. It is believed that the market in the US due to trending opportunities will witness significant growth rate as well as speedy expansion.

Table of Contents

Table of Contents

1. US Diabetes Drugs Market - Prevalence & Statistics

2. US Diabetes Drugs Market Overview

  • 2.1 Current Market Scenario
  • 2.2 Clinical Trials Landscape

3. US Insulins Based Drugs - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 3.1 Insulin Lispro
  • 3.2 Insulin Glargine
  • 3.3 Insulin Aspart
  • 3.4 Insulin Detemir
  • 3.5 Insulin Regular
  • 3.6 Insulin Aspart / Insulin Aspart Protamine
  • 3.7 Insulin Degludec
  • 3.8 Insulin Glulisine
  • 3.9 Insulin Inhalation
  • 3.10 Insulin Isophane / Insulin Regular
  • 3.11 Insulin Isophane
  • 3.12 Insulin Lispro / Insulin Lispro Protamine

4. Non-Sulfonylureas - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 4.1 Metformin

5. Sulfonylureas - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 5.1 Chlorpropamide
  • 5.2 Glimepiride
  • 5.3 Glyburide
  • 5.4 Glipizide
  • 5.5 Tolazamide
  • 5.6 Tolbutamide

6. Thiazolidinediones - Branded & Generic Availability, Dosage, Patent & Price Analysis

  • 6.1 Pioglitazone
  • 6.2 Rosiglitazone

7. Incretin mimetics - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 7.1 Liraglutide
  • 7.2 Exenatide
  • 7.3 Semaglutide
  • 7.4 Dulaglutide
  • 7.5 Lixisenatide

8. Dipeptidyl peptidase 4 inhibitors - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 8.1 Sitagliptin
  • 8.2 Saxagliptin
  • 8.3 Linagliptin
  • 8.4 Alogliptin

9. SGLT-2 inhibitors - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 9.1 Canagliflozin
  • 9.2 Ertugliflozin
  • 9.3 Empagliflozin
  • 9.4 Dapagliflozin

10. Meglitinides - Branded & Generic Availability, Dosage, Patent & Price Analysis

  • 10.1 Repaglinide
  • 10.2 Nateglinide

11. Alpha-glucosidase inhibitors - Branded & Generic Availability, Dosage, Patent & Price Analysis

  • 11.1 Miglitol
  • 11.2 Acarbose

12. Combinational - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

  • 12.1 Metformin/Sitagliptin
  • 12.2 Glimepiride/Pioglitazone
  • 12.3 Glyburide/Metformin
  • 12.4 Dapagliflozin/Metformin
  • 12.5 Empagliflozin/Metformin
  • 12.6 Glipizide/Metformin
  • 12.7 Linagliptin/Metformin
  • 12.8 Metformin/Pioglitazone
  • 12.9 Metformin / Saxagliptin (Kombiglyze XR)
  • 12.10 Alogliptin / Metformin (Kazano)
  • 12.11 Alogliptin / Pioglitazone (Oseni)
  • 12.12 Canagliflozin/Metformin (Invokamet/ Invokamet XR)
  • 12.13 Dapagliflozin / Saxagliptin (Qtern)
  • 12.14 Empagliflozin / Linagliptin / Metformin
  • 12.15 Empagliflozin / Linagliptin (Glyxambi)
  • 12.16 Ertugliflozin / Metformin (Segluromet)
  • 12.17 Ertugliflozin / Sitagliptin (Steglujan)

13. Other Antidiabetic Drugs - Branded & Generic Availability, Dosage, Patent & Price Analysis

  • 13.1 Bromocriptine (Cycloset)
  • 13.2 Colesevelam (Welchol)
  • 13.3 Pramlintide (Symlin)

14. Compititive Landscape

  • 14.1 AstraZeneca
  • 14.2 Boehringer Ingelheim
  • 14.3 Daiichi Sankyo
  • 14.4 Eli Lilly
  • 14.5 GSK
  • 14.6 Janssen Pharma
  • 14.7 Merck
  • 14.8 Novartis
  • 14.9 Novo Nordisk
  • 14.10 Pfizer
  • 14.11 Sanofi
  • 14.12 Takeda

List of Figures

  • Figure 1-1: US - Estimated Diabetic Population (Million), 2019, 2025, 2030 & 2045
  • Figure 1-2: US - Undiagnosed & Diagnosed Diabetic Population (Million), 2019
  • Figure 1-3: US - Undiagnosed & Diagnosed Diabetic Population (%), 2019
  • Figure 1-4: US - Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 & 2045
  • Figure 1-5: US - Diabetic Population by Type (Million), 2019
  • Figure 1-6: US - Diabetic Population by Type (%), 2019
  • Figure 1-7: US - Type 1 Diabetes Cases by Age (Million), 2019
  • Figure 1-8: US - Maximum Diabetic Prevalence Rate by States (%), 2020
  • Figure 1-9: US - Minimum Diabetic Prevalence Rate by States (%), 2020
  • Figure 2-1: US - Diabetes Drug Market Opportunity (US$ Billion), 2019 - 2026
  • Figure 2-2: Global - Diabetes Drug Market Opportunity (US$ Billion), 2019 - 2026
  • Figure 2-3: North America - Diabetes Drug Market Size US v/s Others (US$ Billion), 2020
  • Figure 2-4: US - Insulin Market Opportunity (US$ Billion), 2019 - 2026
  • Figure 2-5: US - Diabetes Drug Market by Product (US Billion), 2020
  • Figure 2-6: US - Diabetes Drug Market by Product (%), 2020
  • Figure 2-7: US - Number of Diabetes Drug Clinical Pipeline by Phase, 2021 - 2026
  • Figure 2-8: US - Number of Diabetes Drugs in Clinical Pipeline by Drug Class, 2021 - 2026
  • Figure 2-9: US - Number of Diabetes Drugs in Clinical Pipeline by Organization, 2021 - 2026
  • Figure 2-10: US - Number of Diabetes Drugs in Clinical Pipeline by Patient Segment, 2021 - 2026
  • Figure 3-1: US - Insulin Lispro FDA Approval & Patent Expiration Year
  • Figure 3-2: US - FDA Approval History by Brand Name
  • Figure 3-3: Humalog - Cost of Supply of 3ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-4: Humalog - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-5: Humalog KwikPen - Cost of 15ml & Per Unit Cost of Injectable Solution (US$), February'2021
  • Figure 3-6: Humalog KwikPen - Cost of 6ml & Per Unit Cost of Subcutaneous Solution (US$), February'2021
  • Figure 3-7: Admelog - Cost of Supply of 3ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-8: Admelog - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-9: Lyumjev - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-10: Humalog Junior KwikPen - Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-11: Insulin Lipro - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-12: Insulin Lispro - Price Per ml By Brand Name (US$)
  • Figure 3-13: Global - Humalog Annual Sales (US$ Million), 2017-2020
  • Figure 3-14: Global - Admelog Annual Sales (US$ Million), 2018 & 2019
  • Figure 3-15: US - Admelog Annual Sales (US$ Million), 2018 & 2019
  • Figure 3-16: Admelog - Annual Sales by Region (US$ Million), 2019
  • Figure 3-17: Admelog - Annual Sales by Region (%), 2019
  • Figure 3-18: Global - Admelog Quarterly Sales (US$ Million), 2019
  • Figure 3-19: US - Admelog Quarterly Sales (US$ Million), 2019
  • Figure 3-20: Global - Admelog Quarterly Sales (US$ Million), 2020
  • Figure 3-21: US - Insulin Glagrine FDA Approval & Patent Expiration Year
  • Figure 3-22: Insulin Glagrine - FDA Approval History by Brand
  • Figure 3-23: Lantus - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 3-24: Basaglar - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 3-25: Toujeo - Cost of Supply of 4.5ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 3-26: Lantus Solostar- Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 3-27: Semglee - ost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 3-28: Global - Lantus Annual Sales (US$ Million), 2017-2019
  • Figure 3-29: US - Lantus Annual Sales (US$ Million), 2017- 2019
  • Figure 3-30: Lantus - Annual Sales by Region (US$ Million), 2019
  • Figure 3-31: Lantus - Annual Sales by Region (%), 2019
  • Figure 3-32: Global - Lantus Quarterly Sales (US$ Million), 2019
  • Figure 3-33: US -Lantus Quarterly Sales (US$ Million), 2019
  • Figure 3-34: Global - Lantus Quarterly Sales (US$ Million), 2020
  • Figure 3-35: US - Lantus Quarterly Sales (US$ Million), 2020
  • Figure 3-36: Lantus - Annual Sales by Region (%), 2020
  • Figure 3-37: Global -Basaglar Annual Sales (US$ Million), 2017-2020
  • Figure 3-38: Global - Toujeo Annual Sales (US$ Million), 2017-2019
  • Figure 3-39: US - Toujeo Annual Sales (US$ Million), 2017- 2019
  • Figure 3-40: Toujeo - Annual Sales by Region (US$ Million), 2019
  • Figure 3-41: Toujeo - Annual Sales by Region (%), 2019
  • Figure 3-42: Global - Toujeo Quarterly Sales (US$ Million), 2019
  • Figure 3-43: US - Toujeo Quarterly Sales (US$ Million), 2019
  • Figure 3-44: Global - Toujeo Quarterly Sales (US$ Million), 2020
  • Figure 3-45: US - Toujeo Quarterly Sales (US$ Million), 2020
  • Figure 3-46: Toujeo - Annual Sales by Region (%), 2020
  • Figure 3-47: US - Insulin Aspart FDA Approval & Patent Expiration Year
  • Figure 3-48: US - FDA Approval History by Brand
  • Figure 3-49: Novolog - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), Fbruary'2021
  • Figure 3-50: Novolog PenFill - Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-51: Fiasp - Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-52: Fiasp - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-53: Insulin Aspart - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-54: Global - Fiasp Annual Sales (US$ Million), 2018-2020
  • Figure 3-55: US - Fiasp Annual Sales (US$ Million), 2018-2020
  • Figure 3-56: Fiasp - Annual Sales by Region (%), 2019
  • Figure 3-57: Fiasp - Annual Sales by Region (%), 2020
  • Figure 3-58: US - Insulin Detemir FDA Approval & Patent Expiration Year
  • Figure 3-59: Levemir - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-60: Global - Levemir Annual Sales (US$ Million), 2018-2020
  • Figure 3-61: US - Levemir Annual Sales (US$ Million), 2018-2020
  • Figure 3-62: Levemir - Annual Sales by Region (%), 2019
  • Figure 3-63: Levemir - Annual Sales by Region (%), 2020
  • Figure 3-64: US - Insulin Regular FDA Approval & Patent Expiration Year
  • Figure 3-65: Insulin Regular - FDA Approval Year by Brand
  • Figure 3-66: Humulin - Cost of Supply of 3ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-67: Humulin - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-68: Novolin - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-69: Humulin R U-500 - Cost of Supply of 20ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-70: Humulin KwikPen- Cost of Supply of 6ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 3-71: Myxredlin- Cost of Supply of 1200ml & Per Unit Price of Intravenous Solution (US$), February'2021
  • Figure 3-72: Global - Humulin Annual Sales (US$ Million), 2017-2020
  • Figure 3-73: Novolog Mix 70/30 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 3-74: Novolog Mix 70/30 FlexPen - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 3-75: Insulin Aspart/Insulin Aspart Protamine - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 3-76: Insulin Aspart/Insulin Aspart Protamine - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 3-77: Global - NovoMix Annual Sales (US$ Million), 2018-2020
  • Figure 3-78: US - NovoMix Annual Sales (US$ Million), 2018-2020
  • Figure 3-79: NovoMix - Annual Sales by Region (%), 2019
  • Figure 3-80: NovoMix - Annual Sales by Region (%), 2020
  • Figure 3-81: US - Insulin Degludec FDA Approval & Patent Expiration Year
  • Figure 3-82: Tresiba- Cost of Supply of 10ml & Per Unit Price of 100units/ml Subcutaneous Solution (US$), February'2021
  • Figure 3-83: Tresiba- Cost of Supply of 15ml & Per Unit Price of 100units/ml Subcutaneous Solution (US$), February'2021
  • Figure 3-84: Tresiba- Cost of Supply of 9ml & Per Unit Price of 200units/ml Subcutaneous Solution (US$), February'2021
  • Figure 3-85: Global - Tresiba Annual Sales (US$ Million), 2018-2020
  • Figure 3-86: US - Tresiba Annual Sales (US$ Million), 2018-2020
  • Figure 3-87: Tresiba - Annual Sales by Region (%), 2019
  • Figure 3-88: Tresiba - Annual Sales by Region (%), 2020
  • Figure 3-89: US - Insulin Glusine FDA Approval & Patent Expiration Year
  • Figure 3-90: US - FDA Approval Year by Brand
  • Figure 3-91: Apidra - Cost of Supply of 10ml & Per Unit Price of injectable solution (US$), February'2021
  • Figure 3-92: Global - Apidra Annual Sales (US$ Million), 2017-2019
  • Figure 3-93: US - Apidra Annual Sales (US$ Million), 2017- 2019
  • Figure 3-94: Apidra - Annual Sales by Region (US$ Million), 2019
  • Figure 3-95: Apidra - Annual Sales by Region (%), 2019
  • Figure 3-96: Global - Apidra Quarterly Sales (US$ Million), 2019
  • Figure 3-97: US - Apidra Quarterly Sales (US$ Million), 2019
  • Figure 3-98: Global - Apidra Quarterly Sales (US$ Million), 2020
  • Figure 3-99: US - Apidra Quarterly Sales (US$ Million), 2020
  • Figure 3-100: Apidra - Annual Sales by Region (%), 2020
  • Figure 3-101: Afrezza - Cost of Supply of 90 Powders & Per Unit Cost of 4 Units Powder (US$), February'2021
  • Figure 3-102: Afrezza - Cost of Supply of 90 Powders & Per Unit Cost of 8 Units Powder (US$), February'2021
  • Figure 3-103: Afrezza - Cost of Supply of 90 Powders & Per Unit Cost of 12 Units Powder (US$), February'2021
  • Figure 3-104: Insulin Isophane/Insulin Regular - FDA Approval Year by Brand
  • Figure 3-105: Humulin 70/30 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 3-106: Humulin 70/30 - Cost of Supply of 3ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 3-107: Humulin 70/30 Pen - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 3-108: Novolin 70/30 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 3-109: ReliON - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 3-110: Insulin Isophane - FDA Approval Year by Brand
  • Figure 3-111: Humulin N - Cost of Supply of 3ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 3-112: Humulin N - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 3-113: Humulin N Pen - Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-114: Novolin N - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February'2021
  • Figure 3-115: Humalog Mix 50/50 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 3-116: Humalog Mix 50/50 Pen - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 3-117: Humalog Mix 75/25 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 3-118: Humalog Mix 50/50 Pen - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Suspension (US$), February'2021
  • Figure 4-1: Metformin - FDA Approval & 1st Generic Approval Year
  • Figure 4-2: Metformin - FDA Approval Year by Brand
  • Figure 4-3: US - Glumetza Patent Approval & Expiration Year
  • Figure 4-4: US - Riomet Patent Approval & Expiration Year
  • Figure 4-5: Glumetza - Cost of Supply of 100 Tablets & Per Unit Price of 500mg Oral Tablet (US$), February'2021
  • Figure 4-6: Glumetza - Cost of Supply of 90 Tablets & Per Unit Price of 1000mg Oral Tablet (US$), February'2021
  • Figure 4-7: Glumetza - Per Unit Cost of 500mg & 100mg Oral Tablet (US$), February'2021
  • Figure 4-8: Glumetza - Maximum & Minimum Recommended Dose (mg)
  • Figure 4-9: Riomet - Cost of Supply of 118ml & Per Unit Price of Oral Soltuion (US$), February'2021
  • Figure 4-10: Riomet - Cost of Supply of 473ml & Per Unit Price of Oral Soltuion (US$), February'2021
  • Figure 4-11: Riomet - Maximum & Minimum Recommended Dose (mg)
  • Figure 4-12: Riomet - Cost of Supply of 118ml & 473ml of Oral Soltuion (US$), February'2021
  • Figure 4-13: Metformin - Cost of Supply of 30, 90 & 100 Oral Tablets (500mg) (US$), February'2021
  • Figure 4-14: Metformin - Cost of Supply of 30, 90 & 100 Oral Tablets (850mg) (US$), February'2021
  • Figure 4-15: Metformin - Cost of Supply of 30, 90 & 100 Oral Tablets (1000mg) (US$), February'2021
  • Figure 4-16: Metformin - Cost of Supply of 30, 90 & 100 Oral ER Tablets (750mg) (US$), February'2021
  • Figure 5-1: Chlorpropamide - Cost of Supply of 30 & 60 Oral Tablets (250mg) (US$), February'2021
  • Figure 5-2: Chlorpropamide - Cost of Supply of 30 & Per Unit Price of Oral Tablets (100mg) (US$), February'2021
  • Figure 5-3: Chlorpropamide - Maximum & Minimum Recommended Dose (mg)
  • Figure 5-4: Glimepiride - FDA Approval & 1st Generic Approval Year
  • Figure 5-5: US - Glimepiride Patent Approval & Expiration Year
  • Figure 5-6: Amaryl - Cost of Supply of 100 Tablets & Per Unit Price of 1mg Oral Tablet (US$), February'2021
  • Figure 5-7: Amaryl - Cost of Supply of 100 Tablets & Per Unit Price of 2mg Oral Tablet (US$), February'2021
  • Figure 5-8: Amaryl - Cost of Supply of 100 Tablets & Per Unit Price of 4mg Oral Tablet (US$), February'2021
  • Figure 5-9: Glimepiride - Cost of Supply of 30, 90 & 100 Oral Tablets (1mg) (US$), February'2021
  • Figure 5-10: Glimepiride - Cost of Supply of 30, 90 & 100 Oral Tablets (2mg) (US$), February'2021
  • Figure 5-11: Glimepiride - Cost of Supply of 30, 90 & 100 Oral Tablets (4mg) (US$), February'2021
  • Figure 5-12: Glimepiride - Maximum & Minimum Recommended Dose (mg)
  • Figure 5-13: Glyburide - FDA Approval & 1st Generic Approval Year
  • Figure 5-14: DiaBeta - Cost of Supply of 50 Tablets & Per Unit Price of 1.25mg Oral Tablet (US$), February'2021
  • Figure 5-15: DiaBeta - Cost of Supply of 100 Tablets & Per Unit Price of 2.25mg Oral Tablet (US$), February'2021
  • Figure 5-16: DiaBeta - Cost of Supply of 100 Tablets & Per Unit Price of 5mg Oral Tablet (US$), February'2021
  • Figure 5-17: Glynase PresTab - Cost of Supply of 100 Tablets & Per Unit Price of 1.5mg Oral Tablet (US$), February'2021
  • Figure 5-18: Glynase PresTab - Cost of Supply of 100 & 1000 Tablets of 3mg Oral Tablet (US$), February'2021
  • Figure 5-19: Glynase PresTab - Cost of Supply of 100 & 500 Tablets of 6mg Oral Tablet (US$), February'2021
  • Figure 5-20: Glyburide- Cost of Supply of 50 & 100 Tablets of 1.5mg Oral Tablet (US$), February'2021
  • Figure 5-21: Glyburide- Cost of Supply of 30, 90 & 100 Tablets of 2.5mg Oral Tablet (US$), February'2021
  • Figure 5-22: Glyburide- Cost of Supply of 30, 90 & 100 Tablets of 5mg Oral Tablet (US$), February'2021
  • Figure 5-23: Glyburide - Cost of Supply of 100 Tablets & Per Unit Price of 1.5mg Micronized Oral Tablet (US$), February'2021
  • Figure 5-24: Glyburide - Cost of Supply of 100 & 1000 Tablets of 3mg Micronized Oral Tablet (US$), February'2021
  • Figure 5-25: Glyburide - Cost of Supply of 100 & 1000 Tablets of 3mg Micronized Oral Tablet (US$), February'2021
  • Figure 5-26: Glyburide - Maximum & Minimum Recommended Dose of Standard Tablet (mg)
  • Figure 5-27: Glyburide - Maximum & Minimum Recommended Dose of Micronized Tablet (mg)
  • Figure 5-28: Glipizide - FDA Approval & 1st Generic Approval Year
  • Figure 5-29: Glucotrol - Cost of Supply of 100 Tablets & Per Unit Price of 5mg Oral Tablet (US$), February'2021
  • Figure 5-30: Glucotrol - Cost of Supply of 100 Tablets & Per Unit Price of 10mg Oral Tablet (US$), February'2021
  • Figure 5-31: Glucotrol XL - Cost of Supply of 30 Tablets & Per Unit Price of 2.5mg Oral Tablet (US$), February'2021
  • Figure 5-32: Glucotrol XL - Cost of Supply of 100 & 500 Tablets of 5mg Oral Tablet (US$), February'2021
  • Figure 5-33: Glucotrol XL - Cost of Supply of 100 & 500 Tablets of 10mg Oral Tablet (US$), February'2021
  • Figure 5-34: Glipizide - Cost of Supply of 30, 90 & 100 Oral Tablets (5mg) (US$), February'2021
  • Figure 5-35: Glipizide - Cost of Supply of 30, 90 & 100 Oral Tablets (10mg) (US$), February'2021
  • Figure 5-36: Glipizide - Cost of Supply of 30 Tablets & Per Unit Price of 2.5mg Oral ER Tablet (US$), February'2021
  • Figure 5-37: Glipizide - Cost of Supply of 100, 500 & 1000 of 5mg Oral ER Tablet (US$), February'2021
  • Figure 5-38: Glipizide - Cost of Supply of 100, 500 & 1000 of 10mg Oral ER Tablet (US$), February'2021
  • Figure 5-39: Glipizide - Maximum Recommended Dose by Oral Tablet (mg/day)
  • Figure 5-40: Tolzamide - Cost of Supply of 90 Tablets & Per Unit Cost of 250mg Tablet (US$), February'2021
  • Figure 5-41: Tolzamide - Cost of Supply of 100 Tablets & Per Unit Cost of 250mg Tablet (US$), February'2021
  • Figure 5-42: Tolzamide - Cost of Supply of 100 Tablets & Per Unit Cost of 500mg Tablet (US$), February'2021
  • Figure 5-43: Tolzamide - Maximum & Minimum Recommended Dose (mg)
  • Figure 5-44: Tolbutamide - Cost of Supply of 100 Tablets & Per Unit Cost of 500mg Tablet (US$), February'2021
  • Figure 5-45: Tolbutamide - Maximum & Minimum Recommended Dose (mg)
  • Figure 6-1: Pioglitazone - FDA Approval & Patent Expiration Year
  • Figure 6-2: Pioglitazone - FDA Approval & 1st Generic Approval Year
  • Figure 6-3: Actos - Cost of Supply of 30, 90 & 500 Tablets of 15mg Oral Tablet (US$), February'2021
  • Figure 6-4: Actos - Cost of Supply of 30 & 500 Tablets of 30mg Oral Tablet (US$), February'2021
  • Figure 6-5: Actos - Cost of Supply of 30 & 500 Tablets of 45mg Oral Tablet (US$), February'2021
  • Figure 6-6: Pioglitazone - Cost of Supply of 30, 90 & 500 Tablets of 15mg Oral Tablet (US$), February'2021
  • Figure 6-7: Pioglitazone - Cost of Supply of 30, 90 & 500 Tablets of 30mg Oral Tablet (US$), February'2021
  • Figure 6-8: Pioglitazone - Cost of Supply of 30, 90 & 500 Tablets of 45mg Oral Tablet (US$), February'2021
  • Figure 6-9: Pioglitazone - Maximum & Minimum Recommended Dose (mg)
  • Figure 6-10: Pioglitazone - Maximum & Minimum Cost of Treatment per Day with Branded & Generic Drugs
  • Figure 6-11: US - Rosiglitazone Patent Approval & Expiration Year
  • Figure 6-12: Rosiglitazone - Cost of Supply of 60 Tablets & Per Unit Cost of 2mg Oral Tablet (US$), February'2021
  • Figure 6-13: Rosiglitazone - Cost of Supply of 30 Tablets & Per Unit Cost of 4mg Oral Tablet (US$), February'2021
  • Figure 6-14: Rosiglitazone - Maximum & Minimum Recommended Dose (mg)
  • Figure 7-1: Liraglutide - FDA Approval & Patent Expiration Year
  • Figure 7-2: Victoza - Cost of Supply of 6ml & Per Unit Cost of Subcutaneous Soltuion (US$), February'2021
  • Figure 7-3: Victoza - Cost of Supply of 9ml & Per Unit Cost of Subcutaneous Soltuion (US$), February'2021
  • Figure 7-4: Victoza - Maximum & Minimum Recommended Dose (mg)
  • Figure 7-5: Global - Victoza Annual Sales (US$ Million), 2018-2020
  • Figure 7-6: US - Victoza Annual Sales (US$ Million), 2018-2020
  • Figure 7-7: Victoza - Annual Sales by Region (%), 2019
  • Figure 7-8: Victoza - Annual Sales by Region (%), 2020
  • Figure 7-9: US - Exenatide FDA Approval & Patent Expiration Year
  • Figure 7-10: US - Exenatide FDA Approval by Brand
  • Figure 7-11: Byetta - Cost of Supply of 1.2ml & Per Unit Cost of 5mcg/0.02ml Subcutaneous Soltuion (US$), February'2021
  • Figure 7-12: Byetta - Cost of Supply of 2.4ml & Per Unit Cost of 10mcg/0.04ml Subcutaneous Soltuion (US$), February'2021
  • Figure 7-13: Bydureon - Cost of Supply of 4 & Per Unit Cost of 2mg Subcutaneous Powder (US$), February'2021
  • Figure 7-14: Bydureon BCise - Cost of Supply of 3.4ml & Per Unit Cost of Subcutaneous Suspension (US$), February'2021
  • Figure 7-15: Global - Bydureon Annual Sales (US$ Million), 2017-2019
  • Figure 7-16: US - Bydureon Annual Sales (US$ Million), 2017-2019
  • Figure 7-17: Bydureon - Annual Sales by Region (%), 2019
  • Figure 7-18: Global - Bydureon Quarterly Sales (US$ Million), 2020
  • Figure 7-19: US - Bydureon Quarterly Sales (US$ Million), 2020
  • Figure 7-20: Bydureon - Annual Sales by Region (%), 2020
  • Figure 7-21: Global - Byetta Annual Sales (US$ Million), 2017-2019
  • Figure 7-22: US - Byetta Annual Sales (US$ Million), 2017-2019
  • Figure 7-23: Byetta - Annual Sales by Region (%), 2019
  • Figure 7-24: Global - Byetta Quarterly Sales (US$ Million), 2020
  • Figure 7-25: US - Byetta Quarterly Sales (US$ Million), 2020
  • Figure 7-26: Byetta - Annual Sales by Region (%), 2020
  • Figure 7-27: Semaglutide - FDA Approval & Patent Expiration Year
  • Figure 7-28: Semaglutide - FDA Approval by Brand
  • Figure 7-29: Ozempic - Cost of Supply of 1.5ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 7-30: Ozempic - Cost of Supply of 3ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 7-31: Ozempic - Maximum & Minimum Recommended Dose (mg)
  • Figure 7-32: Rybelsus - Cost of Supply of 30 Tablets & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 7-33: Rybelsus - Maximum & Minimum Recommended Dose (mg)
  • Figure 7-34: Global - Ozempic Annual Sales (US$ Million), 2018-2020
  • Figure 7-35: US - Ozempic Annual Sales (US$ Million), 2018-2020
  • Figure 7-36: Ozempic - Annual Sales by Region (%), 2019
  • Figure 7-37: Ozempic - Annual Sales by Region (%), 2020
  • Figure 7-38: Global - Rybelsus Annual Sales (US$ Million), 2019 & 2020
  • Figure 7-39: US - Rybelsus Annual Sales (US$ Million), 2019 & 2020
  • Figure 7-40: Rybelsus - Annual Sales by Region (%), 2020
  • Figure 7-41: US - Dulaglutide FDA Approval & Patent Exclusivity Year
  • Figure 7-42: Trulicity - Cost of Supply of 2ml & Per Unit Price of Subcutaneous Solution (US$), February'2021
  • Figure 7-43: Trulicity - Maximum & Minimum Recommended Dose (mg)
  • Figure 7-44: Global - Trulicity Annual Sales (US$ Million), 2017-2020
  • Figure 7-45: US - Lixisenatide FDA Approval & Patent Expiration Year
  • Figure 7-46: Adlyxin - Cost of Supply 6ml & Per Unit Price of Subcutaneous Kit/Solution (US$), February'2021
  • Figure 7-47: Adlyxin - Recommended Initial Dose & Maintenance Dose (mcg)
  • Figure 8-1: US - Sitagliptin FDA Approval & Patent Exclusivity Year
  • Figure 8-2: Januvia - Cost of Supply of 30, 90 & 100 Oral Tablets (US$), February'2021
  • Figure 8-3: Januvia -Recommended Initial Dose & Subsequent Reductions (mg)
  • Figure 8-4: Global - Januvia Annual Sales (US$ Million), 2017-2019
  • Figure 8-5: US - Januvia Annual Sales (US$ Million), 2017-2019
  • Figure 8-6: Januvia - Annual Sales by Region (%), 2019
  • Figure 8-7: Global - Januvia Quarterely Sales (US$ Million), 2020
  • Figure 8-8: US - Saxagliptin FDA Approval & Patent Expiration Year
  • Figure 8-9: Onglyza - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 8-10: Onglyza - Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 8-11: Onglyza - Cost of Daily, Monthly & Annual Treatment (US$)
  • Figure 8-12: Global - Onglyza Annual Sales (US$ Million), 2017-2019
  • Figure 8-13: US - Onglyza Annual Sales (US$ Million), 2017-2019
  • Figure 8-14: Onglyza - Annual Sales by Region (%), 2019
  • Figure 8-15: Global - Onglyza Quarterly Sales (US$ Million), 2020
  • Figure 8-16: US - Onglyza Quarterly Sales (US$ Million), 2020
  • Figure 8-17: Onglyza - Annual Sales by Region (%), 2020
  • Figure 8-18: US - Linagliptin FDA Approval & Patent Expiration Year
  • Figure 8-19: Tradjenta - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 8-20: Tradjenta - Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 8-21: Tradjenta - Cost of Supply of 100 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 8-22: Tradjenta - Cost of Daily, Monthly & Annual Treatment (US$)
  • Figure 8-23: US - Alogliptin Patent Approval & Expiration Year
  • Figure 8-24: US - Alogliptin FDA Approval & Patent Expiration Year
  • Figure 8-25: Nesina - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 8-26: Nesina -Recommended Initial Dose & Subsequent Reductions (mg)
  • Figure 9-1: US - Canagliflozin Patent Approval & Expiration Year
  • Figure 9-2: Invokana - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 9-3: Invokana - Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 9-4: Invokana - Maximum & Minimum Recommended Dose (mg)
  • Figure 9-5: Global - Invokana Annual Sales (US$ Million), 2017-2019
  • Figure 9-6: US - Invokana Annual Sales (US$ Million), 2017-2019
  • Figure 9-7: Invokana - Annual Sales by Region (%), 2019
  • Figure 9-8: Global - Invokana Quarterly Sales (US$ Million), 2019 & 2020
  • Figure 9-9: US - Invokana Quarterly Sales (US$ Million), 2019 & 2020
  • Figure 9-10: Invokana - Annual Sales by Region (%), 2020
  • Figure 9-11: US - Ertugliflozin FDA Approval & Patent Exclusivity Year
  • Figure 9-12: US - Ertugliflozin Patent Approval & Expiration Year
  • Figure 9-13: Steglatro - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 9-14: Steglatro - Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 9-15: Steglatro - Cost of Supply of 500 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 9-16: Steglatro - Maximum & Minimum Recommended Dose (mg)
  • Figure 9-17: US - Ertugliflozin Patent Approval & Expiration Year
  • Figure 9-18: Jardiance - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 9-19: Jardiance - Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 9-20: Jardiance - Maximum & Minimum Recommended Dose (mg)
  • Figure 9-21: Global - Jardiance Annual Sales (US$ Million), 2017-2020
  • Figure 9-22: US - Linagliptin FDA Approval & Patent Expiration Year
  • Figure 9-23: US - Dapagliflozin Patent Approval & Expiration Year
  • Figure 9-24: Farxiga - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 9-25: Farxiga - Maximum & Minimum Recommended Dose (mg)
  • Figure 9-26: Global - Farxiga Annual Sales (US$ Million), 2017-2019
  • Figure 9-27: US - Farxiga Annual Sales (US$ Million), 2017-2019
  • Figure 9-28: Farxiga - Annual Sales by Region (%), 2019
  • Figure 9-29: Global - Farxiga Quarterly Sales (US$ Million), 2020
  • Figure 9-30: US - Farxiga Quarterly Sales (US$ Million), 2020
  • Figure 9-31: Farxiga - Annual Sales by Region (%), 2020
  • Figure 10-1: Repaglinide - Cost of Supply of 100 & Per Unit Price of Oral Tablet of 0.5mg (US$), February'2021
  • Figure 10-2: Repaglinide - Cost of Supply of 30, 100 & 500 Oral Tablets of 1mg (US$), February'2021
  • Figure 10-3: Repaglinide - Cost of Supply of 100 & 500 Oral Tablets of 2mg (US$), February'2021
  • Figure 10-4: Repaglinide - Maximum & Minimum Recommended Dose (mg)
  • Figure 10-5: Nateglinide - Cost of Supply of 30, 90 & 100 Oral Tablets of 60mg (US$), February'2021
  • Figure 10-6: Nateglinide - Cost of Supply of 30, 90 & 100 Oral Tablets of 120mg (US$), February'2021
  • Figure 11-1: US - Miglitol FDA Approval & Generic Availability Year
  • Figure 11-2: Glyset - Cost of Supply of 100 & Per Unit Price of 25mg Oral Tablet (US$), February'2021
  • Figure 11-3: Glyset - Cost of Supply of 100 & Per Unit Price of 50mg Oral Tablet (US$), February'2021
  • Figure 11-4: Glyset - Cost of Supply of 100 & Per Unit Price of 100mg Oral Tablet (US$), February'2021
  • Figure 11-5: Miglitol - Cost of Supply of 100 & Per Unit Price of 25mg Oral Tablet (US$), February'2021
  • Figure 11-6: Miglitol - Cost of Supply of 100 & Per Unit Price of 50mg Oral Tablet (US$), February'2021
  • Figure 11-7: Miglitol - Cost of Supply of 100 & Per Unit Price of 100mg Oral Tablet (US$), February'2021
  • Figure 11-8: Miglitol - Maximum & Minimum Recommended Dose (mg)
  • Figure 11-9: Acarbose - Cost of Supply of 90, 100 & 1000 Oral Tablets of 25mg (US$), February'2021
  • Figure 11-10: Acarbose - Cost of Supply of 90, 100 & 1000 Oral Tablets of 50mg (US$), February'2021
  • Figure 11-11: Acarbose - Cost of Supply of 90, 100 & 1000 Oral Tablets of 100mg (US$), February'2021
  • Figure 11-12: Acarbose - Maximum Recommended Dose by Weight (mg)
  • Figure 12-1: US - Metformin/Sitagliptin FDA Approval by Brand
  • Figure 12-2: US - Janumet Patent Approval & Expiration Year
  • Figure 12-3: US - Janumet XR Patent Approval & Expiration Year
  • Figure 12-4: Janumet - Cost of Supply of 60, 180 & 1000 Oral Tablets (US$), February'2021
  • Figure 12-5: Janumet XR - Cost of Supply of 60, 180 & 1000 Oral Tablets (US$), February'2021
  • Figure 12-6: Global - Janumet Annual Sales (US$ Million), 2017-2019
  • Figure 12-7: US - Janumet Annual Sales (US$ Million), 2017-2019
  • Figure 12-8: Janumet - Annual Sales by Region (%), 2019
  • Figure 12-9: Global - Janumet Quarterely Sales (US$ Million), 2020
  • Figure 12-10: US - Duetact FDA Approval & Generic ApprovalYear
  • Figure 12-11: US - Duetact Patent Approval & Expiration Year
  • Figure 12-12: Duetact - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 12-13: Glimepiride/Pioglitazone - Cost of Supply of 30 & Per Unit Price of 2mg-30mg Oral Tablet (US$), February'2021
  • Figure 12-14: Glimepiride/Pioglitazone - Cost of Supply of 30 & Per Unit Price of 4mg-30mg Oral Tablet (US$), February'2021
  • Figure 12-15: US - Glyburide/Metformin FDA Approval & Generic Availability Year
  • Figure 12-16: Glucovance - Cost of Supply of 100 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 12-17: Glyburide/Metformin - Cost of Supply of 100 & 500 Oral Tablets of 1.25mg (US$), February'2021
  • Figure 12-18: Glyburide/Metformin - Cost of Supply of 100 & 500 Oral Tablets of 2.5mg (US$), February'2021
  • Figure 12-19: Glyburide/Metformin - Cost of Supply of 100 & 500 Oral Tablets of 2.5mg (US$), February'2021
  • Figure 12-20: Glyburide/Metformin - Maximum & Minimum Recommended Dose (mg)
  • Figure 12-21: US - Dapagliflozin/Metformin Patent Approval & Expiration Year
  • Figure 12-22: Xigduo - Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 12-23: US - Synjardy Patent Approval & Expiration Year
  • Figure 12-24: US - Synjardy XR Patent Approval & Expiration Year
  • Figure 12-25: Synjardy - Cost of Supply of 60 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 12-26: Synjardy - Cost of Supply of 180 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 12-27: Glipizide/Metformin - Cost of Supply of 100 & Per Unit Price of 2.5mg-250mg Oral Tablet (US$), February'2021
  • Figure 12-28: Glipizide/Metformin - Cost of Supply of 100 & Per Unit Price of 2.5mg-500mg Oral Tablet (US$), February'2021
  • Figure 12-29: Glipizide/Metformin - Cost of Supply of 100 & Per Unit Price of 5mg-500mg Oral Tablet (US$), February'2021
  • Figure 12-30: US - Linagliptin/Metformin FDA Approval by Brand
  • Figure 12-31: US - Jantadueto Patent Approval & Expiration Year
  • Figure 12-32: Jantadeuto - Cost of Supply of 60 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 12-33: Jantadeuto - Cost of Supply of 180 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 12-34: Jantadeuto XR - Cost of Supply of 60 & Per Unit Price of 2.5mg-1000mg Oral Tablet (US$), February'2021
  • Figure 12-35: Jantadeuto XR - Cost of Supply of 180 & Per Unit Price of 2.5mg-1000mg Oral Tablet (US$), February'2021
  • Figure 12-36: Jantadeuto XR - Cost of Supply of 30 & Per Unit Price of 2.5mg-1000mg Oral Tablet (US$), February'2021
  • Figure 12-37: Jantadeuto XR - Cost of Supply of 90 & Per Unit Price of 5mg-1000mg Oral Tablet (US$), February'2021
  • Figure 12-38: US - Metformin/Pioglitazone FDA Approval & Generic Availability Year
  • Figure 12-39: US - ActoPlus Met Patent Approval & Expiration Year
  • Figure 12-40: ActoPlus Met - Cost of Supply of 60 & Per Unit Price of Oral Tablet (US$), February'2021
  • Figure 12-41: ActoPlus Met - Cost of Supply of 180 & Per Unit Price ofOral Tablet (US$), February'2021
  • Figure 12-42: Metformin/Pioglitazone - Cost of Supply of 60 & Per Unit Price of 850mg-15mg Oral Tablet (US$), February'2021
  • Figure 12-43: ActoPlus Met - Cost of Supply of 180 & Per Unit Price of 850mg-15mg Oral Tablet (US$), February'2021
  • Figure 12-44: Metformin/Pioglitazone - Cost of Supply of 60 & Per Unit Price of 500mg-15mg Oral Tablet (US$), February'2021
  • Figure 12-45: ActoPlus Met - Cost of Supply of 180 & Per Unit Price of 500mg-15mg Oral Tablet (US$), February'2021
  • Figure 12-46: US - BMS's Kombiglyze XR Patent Issue & Expiration Year
  • Figure 12-47: US - AstraZeneca's Kombiglyze XR Patent Issue & Expiration Year
  • Figure 12-48: Kombiglyze XR - Price for 60 Tablets Supply & Price Per Unit Tablet of 1000mg-2.5mg Dose (US$), February'2021
  • Figure 12-49: Kombiglyze XR - Price for 30 Tablets Supply & Price Per Unit Tablet of 1000mg-2.5mg Dose (US$), February'2021
  • Figure 12-50: Kazano - FDA Approval & Authorized Generic Approval Year
  • Figure 12-51: US - Kazano Patent Issue & Expiration Year
  • Figure 12-52: Kazano - Price for 60 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-53: Kazano Authorized Generic - Price for 60 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-54: Oseni - FDA Approval & Authorized Generic Approval Year
  • Figure 12-55: US - Oseni Patent Issue & Expiration Year
  • Figure 12-56: Oseni - Price for 30 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-57: Oseni Authorized Generic - Price for 30 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-58: Invokamet - FDA Approval Year by Dosage Form
  • Figure 12-59: US - Invokamet Patent Issue & Expiration Year
  • Figure 12-60: Invokamet - Price for 60 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-61: US - Mitsubishi's Invokamet XR Patent Issue & Expiration Year
  • Figure 12-62: US - DepoMed's Invokamet XR Patent Issue & Expiration Year
  • Figure 12-63: Invokamet XR - Price for 60 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-64: US - Qtern Patent Issue & Expiration Year
  • Figure 12-65: Qtern - Price for 30 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-66: Qtern - Minimum & Maximum Daily Dose (mg/day)
  • Figure 12-67: US - Trijardy XR Patent Issue & Expiration Year
  • Figure 12-68: Trijarydy XR - Price for 30 Tablets Supply & Price Per Unit Tablet of 10mg-5mg-1000mg & 25mg-5mg-1000mg Dose (US$), February'2021
  • Figure 12-69: Trijarydy XR - Price for 90 Tablets Supply & Price Per Unit Tablet of 10mg-5mg-1000mg & 25mg-5mg-1000mg Dose (US$), February'2021
  • Figure 12-70: Trijarydy XR - Price for 60 Tablets Supply & Price Per Unit Tablet of 25mg-2.5mg-1000mg and 5mg-2.5mg-1000mg Dose (US$), February'2021
  • Figure 12-71: Trijarydy XR - Price for 180 Tablets Supply & Price Per Unit Tablet of 25mg-2.5mg-1000mg and 5mg-2.5mg-1000mg Dose (US$), February'2021
  • Figure 12-72: US - Cycloset Patent Issue & Expiration Year
  • Figure 12-73: Glyxambi - Price for 30 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-74: Glyxambi - Price for 90 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-75: Glyxambi - Minimum & Maximum Daily Dose (mg/day)
  • Figure 12-76: US -Patent Segluromet Issue & Expiration Year
  • Figure 12-77: Segluromet - Price for 60 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-78: Segluromet - Price for 180 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-79: Segluromet - Price for 500 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), February'2021
  • Figure 12-80: US - Merck's Steglujan Patent Issue & Expiration Year
  • Figure 12-81: US - Pfizer's Steglujan Patent Issue & Expiration Year
  • Figure 12-82: Steglujan - Price for 30 Tablets Supply & Price Per Unit Tablet of Both Dose Regimens (US$), February'2021
  • Figure 12-83: Steglujan - Price for 90 Tablets Supply & Price Per Unit Tablet of Both Dose Regimens (US$), February'2021
  • Figure 12-84: Steglujan - Minimum & Maximum Daily Dose (mg/day)
  • Figure 13-1: US - Cycloset Patent Issue & Expiration Year
  • Figure 13-2: Cycloset - Price for 200 Tablets Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 13-3: Cycloset - Minimum & Maximum Daily Dose (mg/day)
  • Figure 13-4: Cycloset - Minimum & Maximum Daily Treatment Cost (US$), February'2021
  • Figure 13-5: Welchol - FDA Approval Year by Dosage Form
  • Figure 13-6: US - Welchol Patent Issue & Expiration Year
  • Figure 13-7: Welchol - Price for 30 Powders Supply & Price Per Unit of Oral Powder for Reconstitution (US$), February'2021
  • Figure 13-8: Welchol - Price for 180 Tablets Supply & Price Per Unit Tablet (US$), February'2021
  • Figure 13-9: Generic Colesevelam - Price for Various Supplies of Oral Tablet (US$), February'2021
  • Figure 13-10: Colesvelem - Cost of Daily Treatment Using Branded & Generic Tablet (US$), February'2021
  • Figure 13-11: Symlin Pen 60 - Price for 3ml Supply & Price Per ml of Subcutaneous Solution (US$), February'2021
  • Figure 13-12: Symlin Pen 120 - Price for 5.4ml Supply & Price Per ml of Subcutaneous Solution (US$), February'2021
  • Figure 13-13: Symlin - Recommended Dose by Diabetes Type (mcg/Meal), February'2021
Back to Top